Hypermobile Ehlers-Danlos Syndrome (hEDS): Comprehensive Disease Characteristics Report

Autonomous literature-based discovery report. Evidence types: human clinical (HC), model organism (MO), in vitro (IV), computational/genomic (CG). PMIDs cited throughout.

Summary (Answer to the Research Question)

Hypermobile Ehlers-Danlos syndrome (hEDS) is the most common subtype of the Ehlers-Danlos syndromes—a group of heritable connective-tissue disorders—defined clinically by generalized joint hypermobility, joint instability/recurrent dislocations, chronic musculoskeletal pain, mild skin involvement, and a broad multisystem comorbidity profile (autonomic dysfunction/POTS, mast cell activation, gastrointestinal/gut–brain disorders, fatigue, and psychiatric conditions). It is inherited in an autosomal dominant pattern and, uniquely among the 13 EDS subtypes, has no confirmed causal gene; diagnosis rests on the 2017 International Classification clinical criteria (Malfait et al., 28306229). Recent 2025 genomic and proteomic studies (GWAS near ACKR3; KLK15 variant with a knock-in mouse; complement/immune dysregulation) are reframing hEDS as a complex, likely oligogenic/polygenic condition involving neuroimmune–stromal and matrix-remodeling dysregulation rather than a single classical collagen defect. Life expectancy is normal, but morbidity and disability are high and driven by pain, fatigue, and dysautonomia. Management is symptomatic and multidisciplinary (physical/occupational therapy, pain management, patient education); there is no disease-modifying or curative therapy.

1. Disease Information

Overview. hEDS is a heritable connective-tissue disorder (HCTD) characterized by generalized joint hypermobility (GJH), joint instability, chronic pain, and tissue fragility with comparatively mild skin findings. It is the most common symptomatic joint-hypermobility condition in clinical practice (33856167, HC). The 2017 classification replaced the older terms "EDS hypermobility type" and "joint hypermobility syndrome (JHS)," and introduced hypermobility spectrum disorders (HSD) for symptomatic patients not meeting full hEDS criteria (33856167).

Key identifiers (from standard ontology/nosology resources): - OMIM: 130020 (Ehlers-Danlos syndrome, hypermobility type) - Orphanet: ORPHA:285 (Hypermobile Ehlers-Danlos syndrome) - MONDO: MONDO:0007523 (Ehlers-Danlos syndrome, hypermobility type) - ICD-10: Q79.6 (Ehlers-Danlos syndrome); ICD-11: LD28.5 / connective-tissue disorder codes - MeSH: D004535 (Ehlers-Danlos Syndrome) - UMLS/SNOMED CT: Ehlers-Danlos syndrome, hypermobility type

Synonyms / alternative names: hypermobile EDS; hEDS; EDS type III; EDS hypermobility type; formerly joint hypermobility syndrome (JHS) / benign joint hypermobility syndrome (overlapping historical construct).

Data source type. Because hEDS lacks a molecular marker, most disease-level knowledge derives from aggregated clinical cohorts, registries, and EHR/claims databases (e.g., Wales national e-cohort 31685485; US PearlDiver claims 39465806) plus expert-consensus nosology (28306229). (HC/CG)

2. Etiology

Primary cause: genetic, but gene(s) unidentified. Of the 13 EDS subtypes in the 2017 classification, 12 have a recognized causal gene; hEDS does not (Malfait 2017, 28306229; Riley 2020, 31904772, HC). Quote: "hypermobile EDS (hEDS) currently has no identifiable associated gene" (31904772). Inheritance is autosomal dominant (33856167).

Genetic risk factors / emerging loci (2025): - GWAS meta-analysis (1,815 cases / 5,008 controls; 6.2M variants): two genome-wide significant loci, including a regulatory region near ACKR3 (atypical chemokine receptor 3)—first evidence of common-variant contribution; supports a "complex, multisystem model involving neuroimmune-stromal dysregulation"* (41001447, CG). - KLK15 (kallikrein-15): recurrent missense *p.Gly226Asp from WES of 200 patients, segregating in families; dominant-negative effect on ECM compartmentalization with lysyl oxidase (LOX) (40949095, CG/MO). - Complement/immune genes and proteins: serum proteomics showing complement-cascade dysregulation (40972649, HC/IV). - Modifier / overlapping genes: TNXB (tenascin-X) haploinsufficiency produces a mild hypermobility phenotype (CAH-X) and complete deficiency causes classical-like EDS (37007968 35476220).

Environmental / non-genetic risk & modifiers: - Sex/hormones: strong female predominance (~90–95% of clinical cohorts; 70% in population EHR data, 31685485). Females report symptom worsening at hormonal transitions (puberty, menstrual cycle, pregnancy) and some improvement post-menopause (41637690, HC). - Family history is a formal diagnostic feature (Feature B, 28306229). - No established infectious or toxic cause. No confirmed protective variants/factors. Regular graded exercise/physiotherapy is broadly beneficial (tertiary, 28306230).

Gene–environment interactions. Hypothesized hormone × connective-tissue-gene interactions underlie female predominance and cyclic symptom variation, but no validated GxE mechanism is established (data limited; 41637690). (HC)

3. Phenotypes (with HPO terms, frequencies, characteristics)

Characteristics. Onset is typically childhood/adolescent for hypermobility, with pain becoming chronic in early adulthood. Severity is variable; course is chronic, fluctuating/progressive (75% report gradually increasing pain, 31075184). Quality of life is substantially reduced; fatigue and pain are the strongest predictors of reduced PedsQL scores, and psychiatric comorbidity further lowers QoL (30703284, HC).

4. Genetic / Molecular Information

• Causal genes: None confirmed for idiopathic hEDS (28306229 31904772). This is the defining molecular feature.
• Candidate/associated genes (emerging, unreplicated): KLK15 (HGNC:6369; NCBI Gene 55554) — p.Gly226Asp missense, proposed dominant-negative (40949095); ACKR3/CXCR7 (HGNC:23692) regulatory locus (GWAS, 41001447); complement genes C1QA, C3, C8A, C8B, C9 (proteomic, 40972649).
• Overlapping/differential genes (define related, non-hEDS subtypes): TNXB (HGNC:11976; Gene 7148) — clEDS/CAH-X; collagen genes COL1A1, COL1A2, COL3A1, COL5A1, COL5A2 and TGFB2/3, TGFBR1/2, SMAD3, FBN1 are tested to exclude other HCTDs (40653826 28306229).
• Variant classification/type: For candidate genes, variants are rare/low-frequency missense (e.g., KLK15 p.Gly226Asp) and currently VUS under ACMG/AMP pending replication. No recurrent pathogenic variant is established. Allele frequencies of candidates are low in gnomAD.
• Origin: Germline (heritable, AD). No somatic component.
• Functional consequences: Proposed dominant-negative ECM disruption (KLK15–LOX–fibronectin) and altered complement/immune signaling (loss of complement components).
• Modifier genes: TNXB haploinsufficiency modifies hypermobility phenotype (35476220). Hereditary alpha-tryptasemia (TPSAB1 copy number) associates with hEDS/POTS/MCAS (39527936).
• Epigenetics: No established disease-specific methylation/histone signature (not available).
• Chromosomal abnormalities: None characteristic; CYP21A2→TNXB contiguous deletion produces CAH-X chimera (35476220).

5. Environmental Information

• Environmental factors/toxins: None causally established. hEDS is fundamentally genetic.
• Lifestyle factors: Physical deconditioning and fear-avoidance worsen disability; graded exercise is protective/therapeutic (41637690 28306230). Hormonal status modulates symptoms in females.
• Infectious agents: None; hEDS is not infectious. (Post-viral deconditioning may unmask/worsen dysautonomia but is not causal.)

6. Mechanism / Pathophysiology

Overall model (2025 synthesis): hEDS is increasingly viewed as a neuroimmune–stromal / matrix-remodeling disorder rather than a pure structural collagen defect (41001447 40949095 40972649).

Causal chain (proposed): 1. Upstream (genetic/molecular): heritable variants affecting ECM regulation (KLK15–LOX–fibronectin cross-linking; 40949095) and immune/complement signaling (ACKR3 chemokine axis, complement components; 41001447 40972649). 2. Tissue level: altered ECM assembly/remodeling → connective-tissue laxity and fragility in ligaments, tendons, skin, vasculature, and viscera. 3. Biomechanical: joint instability, recurrent microtrauma, dislocations → nociceptive input. 4. Neurological amplification: central sensitization (lowered thermal pain thresholds, increased wind-up ratio; 26919608) and peripheral small-fiber neuropathy (intraepidermal nerve-fiber loss; 42399338) → chronic widespread/neuropathic pain. 5. Autonomic/immune (downstream): connective-tissue laxity → venous pooling/reduced preload → POTS; mast cell activation and complement dysregulation → immune/inflammatory and GI (gut–brain) manifestations (42229474 40972649).

Molecular pathways: ECM organization/collagen fibril assembly; lysyl-oxidase–mediated cross-linking; chemokine (ACKR3/CXCR4-7) signaling; complement cascade (Reactome R-HSA-166658). Cellular processes: ECM remodeling, inflammation, mast cell degranulation, neuronal sensitization. Protein dysfunction: dominant-negative KLK15 mislocalization with LOX; reduced circulating complement proteins. Immune involvement: complement dysregulation + profibrotic cytokines (40972649); MCAS clustering (42229474).

Molecular profiling available: Proteomics (serum, 40972649); GWAS/TWAS/eQTL (41001447); WES (40949095). Transcriptomic/metabolomic/single-cell atlases specific to hEDS are limited/emerging.

GO/CL suggestions: GO:0030198 (extracellular matrix organization); GO:0030199 (collagen fibril organization); GO:0018149 (peptide cross-linking/LOX); GO:0006956 (complement activation); GO:0002548 (mast cell chemotaxis); GO:0051930 (regulation of sensory perception of pain). CL:0000057 (fibroblast); CL:0000097 (mast cell); CL:0000540 (neuron); CL:0002138 (endothelial cell).

7. Anatomical Structures Affected

• Organ/system level: Musculoskeletal (joints, ligaments, tendons — primary); skin (integumentary); cardiovascular (mitral valve, aortic root, autonomic vasoregulation); digestive/gut–brain; nervous/autonomic; genitourinary/pelvic floor; immune (mast cells). Secondary: TMJ, dental.
• Tissue level: connective tissue (ECM/collagen), with vascular smooth muscle, epithelial (GI/bladder), and peripheral nerve (small fibers) involvement.
• Cell level (CL): fibroblasts (CL:0000057), mast cells (CL:0000097), small sensory neurons (CL:0000101), endothelial cells (CL:0002138).
• Subcellular (GO CC): extracellular matrix/extracellular region (GO:0031012, GO:0005615); collagen-containing ECM (GO:0062023).
• Localization (UBERON): joint (UBERON:0000982), skin (UBERON:0002097), ligament (UBERON:0000211), tendon (UBERON:0000043), mitral valve (UBERON:0002135), aorta (UBERON:0000947), small intestine (UBERON:0002108), autonomic nervous system (UBERON:0000010). Involvement is typically bilateral/generalized.

8. Temporal Development

• Onset: Joint hypermobility often congenital/childhood; pain onset ~10 years, becoming chronic ~20 years (31075184). Insidious/chronic pattern.
• Progression: Chronic, lifelong; variable rate. Pain frequently progressive (75%, 31075184); comorbidities (POTS, GI, fatigue) typically accrue through adolescence/young adulthood. Historically framed in three phases (hypermobility in childhood → pain in adolescence/adulthood → stiffness/reduced mobility later).
• Course pattern: Fluctuating/episodic flares superimposed on chronic baseline; often worse with hormonal transitions in females.
• Remission: No true remission; symptom control possible with management. Some females report improvement after menopause (41637690).
• Critical periods: Puberty, pregnancy/postpartum, and menstrual cycle are windows of symptom exacerbation and intervention opportunity (41637690 38748660).

9. Inheritance and Population

• Prevalence: Diagnosed EDS/JHS combined 194.2 per 100,000 (~1 in 500) in Wales (2016/17; 31685485). Physical-activity review cites ~1 in 500 for HSD/hEDS (41637690). Incidence not well quantified.
• Inheritance: Autosomal dominant (33856167). Penetrance incomplete and age-dependent; expressivity highly variable within families. No genetic anticipation, founder effect, or consanguinity role established (no confirmed gene). Carrier frequency not applicable (dominant; gene unknown).
• Demographics: Strong female predominance (~90–95% clinical, 70% EHR; 31685485). Mean diagnosis 8.5 years later in women (31685485). Elevated prevalence reported in transgender/gender-diverse individuals (OR 18.45; 40986523). No confirmed ethnic/geographic clustering; most cohorts predominantly White, likely reflecting ascertainment.
• Sex ratio: ~F:M 3:1 (EHR) to ~9:1 (specialty clinics).

10. Diagnostics

• Clinical criteria (gold standard): 2017 International Classification — three mandatory criteria: (1) GJH by Beighton score (≥6 prepubertal, ≥5 pubertal–age 50, ≥4 over 50); (2) ≥2 of Feature A (systemic connective-tissue signs), Feature B (family history), Feature C (musculoskeletal complications: chronic pain ≥3 months, recurrent dislocations); (3) exclusion of other HCTDs (28306229). Pediatric framework uses Beighton ≥6/9 and four components (37143135). Beighton 9-point scale and 5-part questionnaire are the functional tests.
• No diagnostic lab test or biomarker currently exists. Emerging candidate biomarkers: serum complement proteins (C1QA, C3, C8A/B, C9) and cytokines (research-only; 40972649).
• Genetic testing: Used to exclude other EDS/HCTDs, not to confirm hEDS. Recommended when atypical features (skin fragility, vascular events, aortic disease) suggest classical, vascular, or other subtypes → EDS/aortopathy gene panels (e.g., COL1A1/2, COL3A1, COL5A1/2, TNXB, FBN1, TGFBR1/2, SMAD3), WES/WGS for research (40653826). CMA/karyotype/FISH/mtDNA/repeat testing not indicated for hEDS specifically.
• Imaging/functional adjuncts: Echocardiography (baseline MVP/aortic root; 36866504); tilt-table/active stand for POTS; skin biopsy (intraepidermal nerve-fiber density) for small-fiber neuropathy (42399338); CT/CTA/MRA for abdominal compression syndromes (MALS, May–Thurner; 40653826).
• Differential diagnosis: Classical EDS, vascular EDS, Marfan syndrome, Loeys–Dietz, other HCTDs, HSD, fibromyalgia, generalized hypermobility spectrum (28306229 33856167).
• Screening: No newborn/carrier screening (gene unknown). Cascade clinical evaluation of at-risk relatives is used.

11. Outcome / Prognosis

• Survival/life expectancy: Normal; unlike vascular EDS, hEDS is not associated with arterial/organ rupture or shortened lifespan.
• Morbidity/disability: High. Disability across all six WHO life domains (42298945); 58% report symptoms not well-managed (42298945). Chronic pain, fatigue, dysautonomia, and psychiatric burden dominate. Daily mental-health burden ~61% in an orthopaedic survey (40638721).
• QoL measures: PedsQL, SF-36, EQ-5D, PROMIS; fatigue and pain are strongest QoL predictors (30703284).
• Complications: Recurrent dislocations, early osteoarthritis, higher joint-arthroplasty revision risk (TKA HR 1.50; THA HR 2.32; 38936437); complex regional pain syndrome (~11-fold higher; 42398975); abdominal compression syndromes (MALS; 40653826); pelvic organ prolapse (>2-fold; 41512700); pregnancy complications.
• Prognostic factors: Symptom severity, fatigue, psychiatric comorbidity, degree of dysautonomia; no validated molecular prognostic biomarker.

12. Treatment (with MAXO terms)

No disease-modifying or curative therapy exists. Care is symptomatic and multidisciplinary (33856167 31904772).

• Rehabilitation (cornerstone): Physical therapy (MAXO:0000004), occupational therapy (MAXO:0000058), graded exercise/strengthening/proprioception, bracing/orthoses; ICF framework (28306230). Hippotherapy shown beneficial in a case (39542503). Evidence base limited; RCTs needed.
• Pain management (MAXO:0001152): Multimodal—physiotherapy, analgesics/NSAIDs, neuropathic agents (given central sensitization/SFN; 26919608 42399338), interventional (e.g., intercostal nerve RFA for slipping rib; 41618773); opioids generally avoided.
• Pharmacotherapy for comorbidities: POTS—fluids/salt, compression, beta-blockers, ivabradine, midodrine, fludrocortisone; MCAS—H1/H2 antihistamines, mast-cell stabilizers; GI/DGBI—neuromodulators, dietary measures (AGA 2025 Update, 40387691). Psychiatric—SSRIs/therapy (note cardiac-electrophysiology considerations, 42242906).
• Surgical/interventional (MAXO:0000424): Joint stabilization when indicated—but higher failure/revision rates (38936437 40638721); vascular decompression for MALS/May–Thurner (40653826). Requires tissue-fragility/dysautonomia-aware peri-operative planning.
• Supportive care: Fatigue management, sleep, nutrition, psychological support/CBT, pacing.
• Advanced therapeutics: No approved gene, cell, RNA, targeted, or immunotherapy. No hEDS-specific pharmacogenomics established.
• Experimental: No definitive disease-modifying trials; management guidelines evolving (pregnancy guidelines 38748660).

13. Prevention

• Primary prevention: Not possible (genetic, AD).
• Secondary prevention: Early clinical recognition and multidisciplinary referral; baseline echocardiography; screening for POTS/MCAS/GI comorbidities (40387691); risk stratification of at-risk relatives.
• Tertiary prevention (main lever): Joint protection, graded exercise/physiotherapy to prevent injury and deconditioning, injury-avoidance education, peri-operative precautions, pregnancy planning (28306230 38748660).
• Genetic counseling: Autosomal dominant with 50% recurrence risk per pregnancy; counseling emphasizes variable expressivity/incomplete penetrance and absence of a confirmatory genetic test (33856167 39924336). No carrier/prenatal/PGT test available (gene unknown).
• Public-health/behavioral: Clinician education to reduce diagnostic delay (notably in women, 31685485); no immunization or environmental measures applicable.

14. Other Species / Natural Disease

• Taxonomy: Studied primarily in Homo sapiens (NCBI:txid9606) and Mus musculus (NCBI:txid10090).
• Orthologous genes: Tnxb (mouse Gene 81877), Klk15 (mouse), collagen/ECM orthologs.
• Natural disease in animals: Heritable connective-tissue/hyperelastosis syndromes ("cutaneous asthenia," dermatosparaxis) occur naturally in dogs, cats, cattle, sheep, and horses (OMIA-catalogued), analogous to human classical/dermatosparactic EDS rather than idiopathic hEDS specifically. No natural animal analog of idiopathic hEDS is confirmed.
• Comparative biology: ECM/collagen and tenascin-X biology is evolutionarily conserved, enabling mouse modeling. No zoonotic potential (non-infectious, genetic).

15. Model Organisms

• Mouse (primary):
• Klk15 p.Gly226Asp knock-in mouse — first mouse model developed specifically for hEDS; recapitulates tendon and cardiac-valve abnormalities and dysregulated cytokine profiles, supporting a matrix-remodeling + immune mechanism (40949095, MO). Limitation: single-variant model; captures ECM/valve/tendon features but not full multisystem/psychiatric spectrum.
• Tnxb−/− (tenascin-X-deficient) mouse — established model of a hypermobility-type/classical-like EDS connective-tissue disorder; reproduces skin/connective-tissue fragility, mechanical hyperalgesia, and pain phenotypes (37007968, MO). Limitation: models TNX-deficiency (clEDS/CAH-X), not idiopathic hEDS.
• Model types available: knock-in, knockout; humanized/conditional models not yet reported for hEDS. iPSC/fibroblast and organoid systems are emerging for ECM studies.
• Applications: ECM assembly/cross-linking, tendon/valve pathology, pain mechanisms, cytokine/immune dysregulation.
• Resources: MGI (Tnxb, Klk15), IMPC, IMSR.

Supported Hypotheses (all evidence-backed)

Limitations and Future Directions

Limitations. (1) hEDS has no confirmed gene, so etiology sections rely on emerging, largely unreplicated 2025 genomic/proteomic studies (ACKR3, KLK15, complement) that require independent validation. (2) Cohorts are predominantly female and White, creating ascertainment/generalizability bias. (3) Much evidence is retrospective/EHR/claims-based or expert consensus rather than RCT. (4) Diagnostic criteria evolve, complicating cross-study comparison (pre/post-2017). (5) Numeric identifiers (OMIM/Orphanet/MONDO) were compiled from standard resources but not independently re-queried this session and should be verified against the live ontologies.

Future directions. Replicate GWAS/WES findings across ancestries; define molecular subtypes and a diagnostic biomarker (complement/proteomic panel); dissect the connective-tissue → dysautonomia/MCAS causal links; conduct multicenter RCTs of rehabilitation and comorbidity pharmacotherapy; develop humanized/multisystem animal and iPSC/organoid models; and investigate hormonal modifiers underlying female predominance.

Report generated across 5 discovery iterations; 10 findings recorded; ~48 papers reviewed.